Pivotal study demonstrated a clinically meaningful rate of tumor shrinkage (overall response rate) and duration of response in patients with previously-treated advanced cholangiocarcinoma (CCA) harboring
BridgeBio Pharma (BBIO) Affiliate QED Therapeutics and Partner Helsinn Group Announce FDA Approval of TRUSELTIQ for Patients with Cholangiocarcinoma streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
BILLINGS, Mont. - A man is traveling through Montana as part of a 15,000-mile journey to spread awareness about a rare form of cancer, cholangiocarcinoma.Â
Dave Fleischer was joined by his wife Linda for the first leg of the trip. They passed through Billings on March 26.
Dave and Linda s Fleischer s daughter Sarah passed away from cholangiocarcinoma in 2018. The trip is a way to honor her and, Dave said, to bring hope to those who need it the most. I would say the day we found out it was cholangiocarcinoma, it was like a bomb went off, Dave Fleischer said. That s how I would describe it. And, I think that s the reaction from most people when they re diagnosed with cancer.
Share this article
Share this article
PRINCETON, N.J., April 11, 2021 /PRNewswire/ Taiho Oncology, Inc. today announced efficacy and safety results from the Phase 2 FOENIX-CCA2 trial, a single-arm multicenter Phase 2 study evaluating futibatinib (TAS-120) in patients with intrahepatic cholangiocarcinoma (iCCA) harboring
FGFR2 gene rearrangements including gene fusions who have failed at least one line of therapy. The data were presented online as an oral presentation at the American Association for Cancer Research (AACR) Annual Meeting 2021 Week 1 Clinical Trials Plenary from 2:00 – 3:45 PM ET on April 11, 2021.
In the FOENIX-CCA2 trial, 103 patients with locally advanced or metastatic unresectable iCCA harboring
FGFR2 gene rearrangements including fusions who had received one or more prior lines of systemic therapy received futibatinib 20 mg once daily until disease progression or unacceptable toxicity. The study met its primary endpoint of a greater than 20% object
Sally Jo (Zellar) Hoey December 23, 1943 – January 3, 2021 Our beloved wife and mother, Sally Jo Hoey, passed away peacefully on Sunday, January 3, 2021. She is survived by her loving husband of 54 years, William Edward (Ted) Hoey and her daughter and sons, Julie Hoey (Bill) Miller, Doug (Laura) Hoey and Jay (Alicia) Hoey. Sally is also survived by her “daughters at heart” Marianne (Serge) Benoit and Isabel Sapriza, exchange students who remain close to Sally and the family still today. Sally is also survived by her cherished grandchildren, Liam and Delaney Miller, Will, Molly and Gavin Hoey, Alison and Zachary Kittle, Faye, Reece and Josephine Hoey, and William Benoit; her sisters Martha Zellar and Crystal (Steve) Zellar Hinkle; her nephews Jess (Tiffany) Hartman and Ian Hinkle; grand-niece Avery Hartman; and many lifelong friends. She was predeceased by her sister, Lana Mae Zellar Boots, who passed away on May 2, 2020.